Drugs Made In America appointed Roger Bendelac as Chief Executive Officer, effective February 28, 2026, following the resignation and removal of Lynn Stockwell as CEO, Executive Chair and director.
IndividualLynn StockwellRoger BendelacRoleChief Executive Officer; Executive Chair of the Board; Board memberChief Executive OfficerType of ChangeResigned and removedAppointedEffective DateFebruary 28, 2026 (resignation effective upon receipt)February 28, 2026ReasonRelated to Sponsor withdrawals/overpayments and inability of Sponsor to repay overpayment amountAppointment by the Board following Stockwell's resignation/removalReplacement InfoReplaced by Roger Bendelac as CEON/ABackground DetailsNot disclosedOver 30 years in investment banking and advisory; consultant with Silverbear Inc. since Sept 2025; director roles at Apex AI Solutions and Opencap Global; president of SP Associates Corp. since March 2016 (details per filing)Board/Committee Role ChangesRemoved as Executive Chair and Board memberNot disclosedOriginal SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.